| Co-inhibition of CD73 and A2AR adenosine signaling improves anti-tumor immune responses A Young, SF Ngiow, DS Barkauskas, E Sult, C Hay, SJ Blake, Q Huang, ... Cancer cell 30 (3), 391-403, 2016 | 355 | 2016 |
| Targeting CD73 in the tumor microenvironment with MEDI9447 CM Hay, E Sult, Q Huang, K Mulgrew, SR Fuhrmann, KA McGlinchey, ... Oncoimmunology 5 (8), e1208875, 2016 | 267 | 2016 |
| A new bliss independence model to analyze drug combination data W Zhao, K Sachsenmeier, L Zhang, E Sult, RE Hollingsworth, H Yang Journal of biomolecular screening 19 (5), 817-821, 2014 | 264 | 2014 |
| Arylamine N-Acetyltransferase-1 Is Highly Expressed in Breast Cancers and Conveys Enhanced Growth and Resistance to Etoposide in Vitro PJ Adam, J Berry, JA Loader, KL Tyson, G Craggs, P Smith, J De Belin, ... Molecular cancer research 1 (11), 826-835, 2003 | 142 | 2003 |
| Improving target cell specificity using a novel monovalent bispecific IgG design Y Mazor, V Oganesyan, C Yang, A Hansen, J Wang, H Liu, ... MAbs 7 (2), 377-389, 2015 | 124 | 2015 |
| Enhanced tumor-targeting selectivity by modulating bispecific antibody binding affinity and format valence Y Mazor, KF Sachsenmeier, C Yang, A Hansen, J Filderman, K Mulgrew, ... Scientific Reports 7 (1), 40098, 2017 | 117 | 2017 |
| CD73 regulates stemness and epithelial-mesenchymal transition in ovarian cancer-initiating cells M Lupia, F Angiolini, G Bertalot, S Freddi, KF Sachsenmeier, E Chisci, ... Stem cell reports 10 (4), 1412-1425, 2018 | 113 | 2018 |
| Inhibition of CD73 AMP hydrolysis by a therapeutic antibody with a dual, non-competitive mechanism of action JC Geoghegan, G Diedrich, X Lu, K Rosenthal, KF Sachsenmeier, H Wu, ... MAbs 8 (3), 454-467, 2016 | 111 | 2016 |
| Method and apparatus for monitoring of proteins and cells AB Bahnson, DJ Koebler, CN Arthanassiou, RK Houck, K Sachsenmeier, ... US Patent 6,830,931, 2004 | 95 | 2004 |
| Combining phenotypic and proteomic approaches to identify membrane targets in a ‘triple negative’breast cancer cell type S Rust, S Guillard, K Sachsenmeier, C Hay, M Davidson, A Karlsson, ... Molecular cancer 12, 1-11, 2013 | 82 | 2013 |
| Switching off CD73: a way to boost the activity of conventional and targeted antineoplastic therapies L Antonioli, SV Novitskiy, KF Sachsenmeier, M Fornai, C Blandizzi, ... Drug discovery today 22 (11), 1686-1696, 2017 | 79 | 2017 |
| Identification of anti-tumour biologics using primary tumour models, 3-D phenotypic screening and image-based multi-parametric profiling AM Sandercock, S Rust, S Guillard, KF Sachsenmeier, N Holoweckyj, ... Molecular cancer 14, 1-18, 2015 | 71 | 2015 |
| Small molecule AZD4635 inhibitor of A2AR signaling rescues immune cell function including CD103+ dendritic cells enhancing anti-tumor immunity A Borodovsky, CM Barbon, Y Wang, M Ye, L Prickett, D Chandra, J Shaw, ... Journal for Immunotherapy of Cancer 8 (2), 2020 | 69 | 2020 |
| Adenosine signaling is prognostic for cancer outcome and has predictive utility for immunotherapeutic response B Sidders, P Zhang, K Goodwin, G O'Connor, DL Russell, A Borodovsky, ... Clinical Cancer Research 26 (9), 2176-2187, 2020 | 59 | 2020 |
| Inhibition of Rb and p53 is insufficient for SV40 T-antigen transformation KF Sachsenmeier, JM Pipas Virology 283 (1), 40-48, 2001 | 44 | 2001 |
| Transforming Growth Factor-β1 Inhibits Nucleosomal Fragmentation in Human Keratinocytes following Loss of Adhesion (∗) KF Sachsenmeier, N Sheibani, SJ Schlosser, BL Allen-Hoffmann Journal of Biological Chemistry 271 (1), 5-8, 1996 | 42 | 1996 |
| Therapeutic combinations comprising anti-cd73 antibodies and uses thereof K Sachsenmeier, E Sult, C Hay, E Poon US Patent App. 14/937,565, 2016 | 32 | 2016 |
| Phase ia/b, open-label, multicenter study of AZD4635 (an adenosine A2A receptor antagonist) as monotherapy or combined with durvalumab, in patients with solid tumors EA Lim, JC Bendell, GS Falchook, TM Bauer, CG Drake, JH Choe, ... Clinical Cancer Research 28 (22), 4871-4884, 2022 | 31 | 2022 |
| Selective activation of anti-CD73 mechanisms in control of primary tumors and metastases D Vijayan, DS Barkauskas, K Stannard, E Sult, R Buonpane, K Takeda, ... Oncoimmunology 6 (5), e1312044, 2017 | 30 | 2017 |
| Development of a novel ectonucleotidase assay suitable for high-throughput screening KF Sachsenmeier, C Hay, E Brand, L Clarke, K Rosenthal, S Guillard, ... Journal of biomolecular screening 17 (7), 993-998, 2012 | 28 | 2012 |
